CN111671892A - Application of full-suspension duck embryo retinal cells in vaccine for egg drop syndrome of chickens - Google Patents
Application of full-suspension duck embryo retinal cells in vaccine for egg drop syndrome of chickens Download PDFInfo
- Publication number
- CN111671892A CN111671892A CN202010376819.3A CN202010376819A CN111671892A CN 111671892 A CN111671892 A CN 111671892A CN 202010376819 A CN202010376819 A CN 202010376819A CN 111671892 A CN111671892 A CN 111671892A
- Authority
- CN
- China
- Prior art keywords
- duck embryo
- retinal cells
- virus
- embryo retinal
- full
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000272525 Anas platyrhynchos Species 0.000 title claims abstract description 82
- 210000001161 mammalian embryo Anatomy 0.000 title claims abstract description 79
- 230000002207 retinal effect Effects 0.000 title claims abstract description 64
- 229960005486 vaccine Drugs 0.000 title claims abstract description 38
- 239000000725 suspension Substances 0.000 title claims abstract description 35
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 24
- 241000287828 Gallus gallus Species 0.000 title claims abstract description 18
- 235000013330 chicken meat Nutrition 0.000 title claims abstract description 18
- 241000700605 Viruses Species 0.000 claims abstract description 71
- 241000886677 Duck adenovirus 1 Species 0.000 claims abstract description 19
- 239000000427 antigen Substances 0.000 claims abstract description 12
- 102000036639 antigens Human genes 0.000 claims abstract description 12
- 108091007433 antigens Proteins 0.000 claims abstract description 12
- 239000012646 vaccine adjuvant Substances 0.000 claims abstract description 4
- 229940124931 vaccine adjuvant Drugs 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 238000012258 culturing Methods 0.000 claims description 23
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 16
- 238000011081 inoculation Methods 0.000 claims description 13
- 239000002609 medium Substances 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 238000010257 thawing Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000010261 cell growth Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 244000144977 poultry Species 0.000 abstract description 3
- 235000013594 poultry meat Nutrition 0.000 abstract description 3
- 210000000991 chicken egg Anatomy 0.000 abstract 1
- 235000013601 eggs Nutrition 0.000 description 24
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 229940031551 inactivated vaccine Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 101710112752 Cytotoxin Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- 231100000238 embryotoxicity Toxicity 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the technical field of poultry vaccines, in particular to application of full-suspension duck embryo retinal cells in a vaccine for egg drop syndrome of chickens. The application of the full-suspension duck embryo retinal cells in the egg drop syndrome vaccine of chickens comprises the steps of inoculating K-11 strain virus into the full-suspension duck embryo retinal cells to culture to obtain antigen solution of egg drop syndrome virus, and mixing the antigen solution of egg drop syndrome virus with a vaccine adjuvant to obtain the egg drop syndrome vaccine of chickens. The application of the fully suspended duck embryo retinal cells in the chicken egg drop syndrome vaccine can improve the vaccine titer and has low cost.
Description
Technical Field
The invention relates to the technical field of poultry vaccines, in particular to application of full-suspension duck embryo retinal cells in a vaccine for egg drop syndrome of chickens.
Background
Egg Drop Syndrome (EDS) is a common infectious virus of laying hens caused by Egg Drop Syndrome Virus (EDSV), and although the lethality rate of the disease is low, the egg yield of infected hens is seriously reduced, and the egg quality is influenced. The affected chickens mainly show symptoms of mass-production laying rate reduction, abnormal eggshells, egg body deformity, poor egg quality and the like. The disease can reduce the laying rate of laying hens by 30-50%, the breakage rate of eggs reaches 40%, the shell-free eggs and the soft-shell eggs can reach 15%, and serious economic loss is caused to the chicken industry.
At present, the production of vaccines related to egg drop syndrome in China mainly adopts the inoculation of duck embryos for culture and preparation of the vaccines, because SPF duck embryos are expensive and small in quantity, the actual production requirements cannot be met, but non-duck embryos cannot guarantee the source of the duck embryos, the duck embryos possibly contain other viruses, the titer of the bred EDSV is greatly influenced, and the quality difference of the vaccines in different batches is huge. Meanwhile, the virus suspension cultured by the duck embryo contains a large amount of heterologous protein, so that the side effect of the vaccine is large.
In recent years, poultry vaccine related products are all strived to separate from embryo-derived production, and new production media, such as subunit vaccines and cell-derived vaccines, are searched. EB66 cells were also reported to produce a vaccine against egg drop syndrome, but the virus titer was around 17log2, the immune antibody level after mating was between 10-12log2, and the HA titer was still low.
Disclosure of Invention
The invention aims to provide application of full-suspension duck embryo retinal cells in a vaccine for egg drop syndrome of chickens, and the full-suspension duck embryo retinal cells are applied to the vaccine for egg drop syndrome of chickens, so that the titer of the vaccine can be improved, and the cost is low.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
The invention provides application of full-suspension duck embryo retinal cells in a vaccine for egg drop syndrome of chickens, which is characterized in that K-11 strain virus is inoculated into the full-suspension duck embryo retinal cells to be cultured to obtain antigen solution of the egg drop syndrome virus, and then the antigen solution of the egg drop syndrome virus is mixed with a vaccine adjuvant to obtain the vaccine for egg drop syndrome of chickens.
Further, in some embodiments of the invention, the fully suspended duck embryo retinal cells are firstly revived and cultured, then the K-11 strain virus is inoculated into the cultured fully suspended duck embryo retinal cells, and simultaneously DMEM medium is added for culture, and then the virus is collected and frozen and thawed.
Further, in some embodiments of the present invention, the resuscitating and culturing of the fully suspended duck embryo retinal cells comprises the following steps: taking out the fully suspended duck embryo retinal cells from a liquid nitrogen tank, rapidly melting the cells in a water bath at 37 ℃, centrifuging for 5 minutes at 200g, removing supernatant, suspending the fully suspended duck embryo retinal cells by using 30ml of cell growth solution, inoculating the fully suspended duck embryo retinal cells into a 125ml shake flask, placing the shake flask in a shaking table at the set rotation speed of 160r/min and the temperature of 37 ℃ and CO2Culturing at 5% concentration for 2-3 days until the cell density reaches at least 6.0 × 106When the cells are used for per ml, the fully suspended duck embryo retinal cells are expanded and passaged to 250ml shake flasks, and the initial cell density is 1.0 × 106And/ml, placing in a shaking table, and continuing culturing.
Further, in some embodiments of the present invention, the whole suspension of the duck embryo retinal cells is expanded to 250ml of shake flask, and then cultured until the cell density is 2.0 × 106/-1.0×107And/ml, inoculating the K-11 strain virus into the fully suspended duck embryo retinal cells.
Further, in some embodiments of the present invention, the virus of the above K-11 strain is inoculated in an amount of 0.0001 to 0.01 mol.
Further, in some embodiments of the invention, the above K-11 strain virus is cultured at a temperature of 35-39 ℃ after being inoculated into the fully suspended duck embryo retinal cells.
Further, in some embodiments of the invention, the above K-11 strain virus is cultured for 3-5 days after being inoculated into the fully suspended duck embryo retinal cells.
Further, in some embodiments of the present invention, the DMEM medium is added in an amount of 0 to 20% by volume of the culture solution.
Further, in some embodiments of the invention, the K-11 strain virus is inoculated into cultured whole suspension duck embryo retinal cells, and the cells are cultured in a shaking table at a rotation speed of 160r/min and CO2The concentration was 5%.
The preparation method of the egg drop syndrome vaccine and the vaccine provided by the invention have the following beneficial effects:
thus, the K-11 strain virus is inoculated to the fully suspended duck embryo retinal cells to be cultured to obtain the antigen solution of the egg drop syndrome virus, the cost is low, and the obtained vaccine has high titer and strong immunocompetence.
The invention adopts full suspension cell detection to proliferate egg drop syndrome virus, the method is quick and simple, the cell source is clear and definite, and the invention avoids the immunogenicity influence caused by overhigh protein impurities caused by duck embryo production and also reduces the risk of exogenous virus caused by embryo source. The technology has short virus culturing time and high virus titer, and the vaccine produced by the technology has high antibody titer and higher economic benefit and market prospect.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present invention will be described in detail below with reference to specific examples.
The invention provides application of full-suspension duck embryo retinal cells in a vaccine for egg drop syndrome of chickens, which is characterized in that K-11 strain virus is inoculated into the full-suspension duck embryo retinal cells to be cultured to obtain antigen solution of the egg drop syndrome virus, and then the antigen solution of the egg drop syndrome virus is mixed with a vaccine adjuvant to obtain the vaccine for egg drop syndrome of chickens. The K-11 strain virus is inoculated to the fully suspended duck embryo retinal cells to be cultured to obtain the antigen solution of the egg drop syndrome virus, the cost is low, and the obtained vaccine has high titer and strong immunocompetence.
Further, in some embodiments of the invention, the fully suspended duck embryo retinal cells are firstly revived and cultured, then the K-11 strain virus is inoculated into the cultured fully suspended duck embryo retinal cells, and simultaneously DMEM medium is added for culture, and then the virus is collected and frozen and thawed. The operation is very simple, and the prepared vaccine has high titer and strong immunocompetence.
Further, in some embodiments of the present invention, the resuscitating and culturing of the fully suspended duck embryo retinal cells comprises the following steps: taking out the fully suspended duck embryo retinal cells from a liquid nitrogen tank, rapidly melting the cells in a water bath at 37 ℃, centrifuging for 5 minutes at 200g, removing supernatant, suspending the fully suspended duck embryo retinal cells by using 30ml of cell growth solution, inoculating the fully suspended duck embryo retinal cells into a 125ml shake flask, placing the shake flask in a shaking table at the set rotation speed of 160r/min and the temperature of 37 ℃ and CO2Culturing at 5% concentration for 2-3 days until the cell density reaches at least 6.0 × 106When the cells are used for per ml, the fully suspended duck embryo retinal cells are expanded and passaged to 250ml shake flasks, and the initial cell density is 1.0 × 106And/ml, placing in a shaking table, and continuing culturing. Therefore, the full-suspension duck embryo retinal cells can be fully revived and cultured to form a full-suspension duck embryo retinal cell receptor culture medium with appropriate density, and the full-suspension duck embryo retinal cells are effectively utilized.
Further, in some embodiments of the present invention, the whole suspension of the duck embryo retinal cells is expanded to 250ml of shake flask, and then cultured until the cell density is 2.0 × 106/-1.0×107And/ml, inoculating the K-11 strain virus into the fully suspended duck embryo retinal cells. Such cell density is more favorable for cell proliferation.
Further, in some embodiments of the present invention, the virus of the above K-11 strain is inoculated in an amount of 0.0001 to 0.01 mol.
Further, in some embodiments of the invention, the above K-11 strain virus is cultured at a temperature of 35-39 ℃ after being inoculated into the fully suspended duck embryo retinal cells. Such an amount of inoculation allows the maximum utilization of the medium while allowing the medium to be loaded. Such a temperature is more favorable for the proliferation of cells.
Further, in some embodiments of the invention, the above K-11 strain virus is cultured for 3-5 days after being inoculated into the fully suspended duck embryo retinal cells. Such a cultivation time can avoid the shortage of the number of the proliferations due to the excessively short time.
Further, in some embodiments of the present invention, the DMEM medium is added in an amount of 0 to 20% by volume of the culture solution. Thus, the nutrient in the culture medium is more sufficient, and the cell proliferation is facilitated.
Further, in some embodiments of the invention, the K-11 strain virus is inoculated into cultured whole suspension duck embryo retinal cells, and the cells are cultured in a shaking table at a rotation speed of 160r/min and CO2The concentration was 5%. Such culture conditions allow for more rapid cell propagation.
The features and properties of the present invention are described in further detail below with reference to examples.
Test example 1: optimum inoculation cell density test for K-11 strain virus
Taking 4 250ml shake flasks to culture the fully suspended duck embryo retinal cells, and respectively culturing to the cell density of about 2.0 × 106/ml、6.0×106/ml、8.0×106/ml、1.0×107Then respectively inoculating the viruses of the egg drop syndrome K-11 strains, simultaneously adding DMEM medium with the volume ratio of 15%, putting into a shaking table, and placing at 160r/min, 37 ℃ and 5% CO2And (5) culturing. Collecting toxin after 96h, freezing and thawing for 1 time, and measuring HA titer and virus content. The results are detailed in table 1.
TABLE 1 test results of optimal cell density for inoculation of K-11 strains of virus
The results showed that the cell density was 8.0 × 10 when inoculated with the egg drop syndrome virus6At the concentration of the virus, the HA titer can reach 23log2, the virus content is the highest, namely 107.6TCID50/0.1ml, so the optimal inoculation density of the cells is 8.0 × 106/ml。
Test example 2: optimum inoculation amount test of K-11 strain virus
3 250ml shake flasks were used to culture the fully suspended duck embryo retinal cells, and the cell density was 8.0 × 106The virus strains of egg drop syndrome K-11 are inoculated with 0.01MOI, 0.001MOI and 0.0001MOI respectively, and DMEM medium with volume ratio of 15% is added into the virus strains, and the virus strains are placed into a shaking table at 160r/min, 37 ℃ and 5% CO2And (5) culturing. Collecting toxin after 96h, freezing and thawing for 1 time, and measuring HA titer and virus content. The results are detailed in table 2.
TABLE 2 optimal inoculation amount test results for K-11 strains of virus
The result shows that the K-11 strain virus is inoculated at 0.001MOI, the HA titer can reach 22log2, the harvested virus content is slightly higher and is 107.8TCID50/0.1ml, so the optimal inoculation amount of the egg drop syndrome virus is determined as 0.001 MOI.
Test example 3: optimum inoculation temperature test for K-11 strain virus
3 250ml shake flasks were used to culture the fully suspended duck embryo retinal cells, and the cell density was 8.0 × 106When the virus is used for every ml, inoculating the K-11 strain of egg drop syndrome according to 0.001MOI, simultaneously adding 15% DMEM culture medium by volume, placing into a shaking table, respectively culturing at 35 deg.C, 37 deg.C and 39 deg.C, with the rotation speed of the shaking table being 160r/min and CO2The culture was carried out at a concentration of 5%. Samples were frozen and thawed 1 time at 48h, 72h, and 96h, respectively, and the HA titers were determined. The results are detailed in Table 3.
TABLE 3 optimal incubation temperature test results for K-11 strains of disease
The results showed that the HA titer could be rapidly increased by culturing at 39 ℃ after inoculation of K-11, but the final virus titer was not as high as that of 37 ℃, so the optimal temperature for culturing K-11 was set at 37 ℃.
Test example 4: optimal virus receiving time of K-11 strain
Taking 1 250ml of shake flask to culture the fully suspended duck embryo retina cells, and culturing the cells until the cell density reaches 8.0 × 106The virus strain K-11 is inoculated according to 0.001MOI, DMEM medium with the volume ratio of 15% is added at the same time, the mixture is placed into a shaking table, the temperature is 35 ℃ and the concentration is 5% CO at 160r/min2Culturing, sampling 72h, 96h and 120h after inoculation, freezing and thawing for 1 time, and determining HA titer and virus content. The results are detailed in Table 4.
TABLE 4 test results of the optimal virus-harvesting time for K-11 strains of disease
The result shows that after the K-11 strain is inoculated and cultured for 96h and 120h, the HA titer is not greatly different, and the virus content result shows that the culture time is slightly higher than 96h and can reach 107.6TCID50/0.1ml, so the optimal virus recovery time after the inoculation of the egg drop syndrome virus is determined as 96 h.
Test example 5: comparative test for DMEM addition
Taking 4 250ml shake flasks to culture the fully suspended duck embryo retinal cells, and culturing the cells to 8.0 × 10 when the cell density is reached6And/ml, inoculating the K-11 strain of egg drop syndrome according to 0.001MOI, simultaneously adding DMEM culture medium with the volume ratio of 0%, 10%, 15% and 20%, respectively, culturing for 96h at 37 ℃ under the condition of 5% CO2, collecting the toxin, freezing and thawing for 1 time, and determining the HA titer and the virus content. The results are detailed in Table 5.
TABLE 5 comparative test results for DMEM addition
Tests of different addition amounts of DMEM show that the HA titer and the virus content of the harvested virus are the highest when 15% of DMEM is added by volume, and are respectively 24log2 and 107.3TCID50/0.1 ml.
Test example 6: immunogenicity research of full-suspension duck embryo retinal cell virus and duck embryo virus
Taking the full-suspension duck embryo retina cell virus and the duck embryo virus, respectively adding formaldehyde solution with final concentration of 0.1%, inactivating for 48 hours at 37 ℃, respectively adding sterilized Tween-80 into the completely inactivated cell virus and the duck embryo virus, uniformly mixing to prepare water phase, and respectively preparing the cell virus oil emulsion inactivated vaccine and the duck embryo virus oil emulsion inactivated vaccine according to the proportion of 2: 1 of oil phase and water phase.
20 SPF chickens of 35 days old are randomly and averagely divided into 2 groups and 10 groups, the cytotoxin oil emulsion inactivated vaccine and the duck embryo cytotoxin oil emulsion inactivated vaccine are respectively injected subcutaneously into the neck, 0.5ml of each group, and 10 chicken non-immunized are taken as a control. On 21, 28 and 35 days after immunization, test chicken blood is collected to separate serum, and the HI antibody in the serum is detected by EDSV-HI antigen. The results are shown in Table 6.
TABLE 6 Total suspension Duck embryo retinal cytotoxicity and Duck embryo toxicity immunogenicity test results
The result shows that the HI antibody average value of the full-suspension duck embryo retina cytotoxic vaccine immunity group is higher than that of the duck embryo cytotoxic vaccine immunity group. Therefore, the full-suspension duck embryo retinal cell cytotoxicity has better immunogenicity,
the preparation method of the egg drop syndrome vaccine and the vaccine provided by the invention have the following beneficial effects: thus, the K-11 strain virus is inoculated to the fully suspended duck embryo retinal cells to be cultured to obtain the antigen solution of the egg drop syndrome virus, the cost is low, and the obtained vaccine has high titer and strong immunocompetence.
The invention adopts full suspension cell detection to proliferate egg drop syndrome virus, the method is quick and simple, the cell source is clear and definite, and the invention avoids the immunogenicity influence caused by overhigh protein impurities caused by duck embryo production and also reduces the risk of exogenous virus caused by embryo source. The technology has short virus culturing time and high virus titer, and the vaccine produced by the technology has high antibody titer and higher economic benefit and market prospect.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (9)
1. The application of the full-suspension duck embryo retinal cells in the vaccine for the egg drop syndrome of chickens is characterized in that: inoculating the K-11 strain virus into the fully suspended duck embryo retinal cells to culture to obtain antigen solution of the egg drop syndrome virus, and mixing the antigen solution of the egg drop syndrome virus with a vaccine adjuvant to obtain the egg drop syndrome vaccine.
2. Use according to claim 1, characterized in that: resuscitating and culturing the full-suspension duck embryo retinal cells, inoculating the K-11 strain virus into the cultured full-suspension duck embryo retinal cells, adding a DMEM (DMEM) culture medium for culturing, and then performing virus harvesting and freeze thawing.
3. Use according to claim 2, characterized in that: the recovery and culture of the fully suspended duck embryo retinal cells comprise the following steps: taking out the full suspension duck embryo retinal cells from a liquid nitrogen tank, rapidly melting the cells in a water bath at 37 ℃, centrifuging for 5 minutes at 200g, removing supernatant, suspending the full suspension duck embryo retinal cells by using 30ml of cell growth medium, and inoculating the full suspension duck embryo retinal cells to the cells125ml of the shake flask, placing the shake flask in a shaking table at a rotation speed of 160r/min and a temperature of 37 ℃ under CO2Culturing at 5% concentration for 2-3 days until the cell density reaches at least 6.0 × 106When the cells are used for per ml, the fully suspended duck embryo retinal cells are expanded and passaged to 250ml shake flasks, and the initial cell density is 1.0 × 106And/ml, placing in a shaking table, and continuing culturing.
4. The use of claim 3, wherein the whole suspension duck embryo retinal cells are expanded to 250ml shake flask, and then cultured until the cell density is 2.0 × 106/-1.0×107And/ml, inoculating the K-11 strain virus into the fully suspended duck embryo retinal cells.
5. Use according to claim 2, characterized in that: the inoculation amount of the K-11 strain virus is 0.0001-0.01 mol.
6. Use according to claim 2, characterized in that: the culture temperature of the K-11 strain virus after being inoculated into the fully suspended duck embryo retinal cells is 35-39 ℃.
7. Use according to claim 2, characterized in that: the culture time of the K-11 strain virus after being inoculated into the fully suspended duck embryo retinal cells is 3-5 days.
8. Use according to claim 2, characterized in that: the addition amount of the DMEM medium is 0-20% of the volume ratio of the culture solution.
9. Use according to claim 2, characterized in that: inoculating the K-11 strain virus into the cultured full-suspension duck embryo retinal cells, and putting the cells into a shaking table for culturing at the rotating speed of 160r/min and CO2The concentration was 5%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010376819.3A CN111671892A (en) | 2020-05-07 | 2020-05-07 | Application of full-suspension duck embryo retinal cells in vaccine for egg drop syndrome of chickens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010376819.3A CN111671892A (en) | 2020-05-07 | 2020-05-07 | Application of full-suspension duck embryo retinal cells in vaccine for egg drop syndrome of chickens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111671892A true CN111671892A (en) | 2020-09-18 |
Family
ID=72451754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010376819.3A Pending CN111671892A (en) | 2020-05-07 | 2020-05-07 | Application of full-suspension duck embryo retinal cells in vaccine for egg drop syndrome of chickens |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111671892A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112359142A (en) * | 2020-11-10 | 2021-02-12 | 成都天邦生物制品有限公司 | Method for determining newcastle disease virus content by using whole suspension cells |
| CN113122508A (en) * | 2021-03-30 | 2021-07-16 | 成都天邦生物制品有限公司 | Infectious bronchitis cell adaptive virus and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229969A1 (en) * | 2008-06-25 | 2011-09-22 | Volker Sandig | Cell Line for Propagation of Highly Attenuated AlphaViruses |
| CN108721615A (en) * | 2018-05-16 | 2018-11-02 | 北京市农林科学院 | A kind of method and its vaccine preparing duck tembusu virus inactivated vaccine |
| CN109593729A (en) * | 2018-12-29 | 2019-04-09 | 肇庆大华农生物药品有限公司 | A kind of fowl Egg Drop syndrome virus cultural method and its application in vaccine |
| CN110129281A (en) * | 2019-05-15 | 2019-08-16 | 成都天邦生物制品有限公司 | A kind of method and application using suspension cell culture newcastle disease virus |
-
2020
- 2020-05-07 CN CN202010376819.3A patent/CN111671892A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229969A1 (en) * | 2008-06-25 | 2011-09-22 | Volker Sandig | Cell Line for Propagation of Highly Attenuated AlphaViruses |
| CN108721615A (en) * | 2018-05-16 | 2018-11-02 | 北京市农林科学院 | A kind of method and its vaccine preparing duck tembusu virus inactivated vaccine |
| CN109593729A (en) * | 2018-12-29 | 2019-04-09 | 肇庆大华农生物药品有限公司 | A kind of fowl Egg Drop syndrome virus cultural method and its application in vaccine |
| CN110129281A (en) * | 2019-05-15 | 2019-08-16 | 成都天邦生物制品有限公司 | A kind of method and application using suspension cell culture newcastle disease virus |
Non-Patent Citations (1)
| Title |
|---|
| INGO JORDAN等: "Continuous cell lines from the Muscovy duck as potential replacement for primary cells in the production of avian vaccines" * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112359142A (en) * | 2020-11-10 | 2021-02-12 | 成都天邦生物制品有限公司 | Method for determining newcastle disease virus content by using whole suspension cells |
| CN113122508A (en) * | 2021-03-30 | 2021-07-16 | 成都天邦生物制品有限公司 | Infectious bronchitis cell adaptive virus and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107267466B (en) | Method for large-scale production of porcine pseudorabies inactivated vaccine | |
| CN107904215B (en) | Full suspension culture method of avian influenza virus | |
| CN108300704B (en) | Method for suspension culture of infectious bronchitis virus by using continuous cell line | |
| CN111632137A (en) | Triple vaccine for feline calicivirus disease, feline infectious rhinotracheitis and feline panleukopenia as well as preparation method and application thereof | |
| CN110237246B (en) | Method for culturing inactivated vaccine for avian influenza (H9) by using full-suspension cells | |
| CN111671892A (en) | Application of full-suspension duck embryo retinal cells in vaccine for egg drop syndrome of chickens | |
| CN109913404B (en) | Preparation method of chicken infectious bursal disease virus live vaccine | |
| CN102268411A (en) | Method for IBDV (Infectious Bursal Disease Virus) serum-free microcarrier suspension culture proliferation | |
| CN110157659B (en) | BHK-21 cell line BHK-21-BP-2 clone strain and application thereof in full suspension cell culture | |
| CN113122508A (en) | Infectious bronchitis cell adaptive virus and application thereof | |
| CN114276981A (en) | Vero-E6 suspension cell strain sVero-E6 adapted to porcine epidemic diarrhea virus and application thereof | |
| CN106237323B (en) | Porcine reproductive and respiratory syndrome purified vaccine and preparation method thereof | |
| CN109593729A (en) | A kind of fowl Egg Drop syndrome virus cultural method and its application in vaccine | |
| CN115627259B (en) | Adaptation method of virus in chick embryo fibroblast | |
| CN111569060A (en) | Preparation method of egg drop syndrome vaccine and vaccine | |
| CN113817688B (en) | Chick embryo culture process of tetravalent influenza virus split vaccine and preparation method of tetravalent influenza virus split vaccine | |
| CN114395536B (en) | Avian adenovirus type 4, 8 and 11 trivalent vaccine and preparation method and application thereof | |
| CN112143714B (en) | Method for producing H7 subtype avian influenza virus inactivated vaccine by using low-immunity chick embryo | |
| CN111411087B (en) | Cyprinus carpioides herpesvirus II type low virulent strain and application thereof | |
| CN104740627B (en) | A kind of large-scale method for producing of pseudo- mad dog attenuated live vaccines for animals | |
| CN102978166A (en) | Method for preparing newcastle disease viruses and vaccines by using serial passage cells, and products thereof | |
| CN103157107A (en) | Chicken Marek's disease vaccine produced by using continuous passage cell line and production method | |
| CN107261132B (en) | Method for producing porcine pseudorabies live vaccine by using bioreactor and product thereof | |
| CN107198771B (en) | Method for producing porcine pseudorabies gE gene deletion virus vaccine by microcarrier suspension culture cells | |
| CN112080478A (en) | Efficient propagation method and application of H5 subtype avian influenza virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20221215 Address after: No.358, lingchi street, Chengdu Economic and Technological Development Zone, Sichuan 610000 Applicant after: CHENGDU TECBOND BIOLOGICAL PRODUCTS CO.,LTD. Address before: No.358, lingchi street, Chengdu Economic and Technological Development Zone, Sichuan 610000 Applicant before: CHENGDU TECBOND BIOLOGICAL PRODUCTS CO.,LTD. Applicant before: Shiji Biotechnology (Nanjing) Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230307 Address after: No.358, lingchi street, Chengdu Economic and Technological Development Zone, Sichuan 610000 Applicant after: Chengdu Shiji biopharmaceutical Co.,Ltd. Address before: No.358, lingchi street, Chengdu Economic and Technological Development Zone, Sichuan 610000 Applicant before: CHENGDU TECBOND BIOLOGICAL PRODUCTS CO.,LTD. Applicant before: Shiji Biotechnology (Nanjing) Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200918 |
|
| RJ01 | Rejection of invention patent application after publication |